Pricing Disclosures
Select state to view state-required pricing disclosures
Colorado
Pursuant to Colorado law, C.R.S. 12-280-308, Merck is required to provide to Colorado prescribers pricing information about certain Merck products, as well as the names of generic products in the same therapeutic class. The generic products listed are not necessarily the generic form of the Merck product. Rather, these drugs could be the generic form of a non-Merck drug in the same therapeutic class. Depending on the number of generic prescription drugs in the therapeutic class, this list may not be inclusive of all. The generic products listed are not necessarily interchangeable with the Merck product, nor should they be implied to have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.
The prices listed reflect Merck’s Wholesale Acquisition Costs for the Merck product. The prices paid by consumers may vary from the prices listed.
- BELSOMRA®
(suvorexant) 5, 10, 15, 20 mg tablets, for oral use, C-IV
- DELSTRIGO®
(doravirine 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg) tablets
Before prescribing DELSTRIGO, please read the accompanying Prescribing Information, including the Boxed Warning about posttreatment acute exacerbation of Hepatitis B.
- DIFICID®
(fidaxomicin) tablets 200 mg | oral suspension 200 mg/5 ml
- ISENTRESS® & ISENTRESS® HD
ISENTRESS® (raltegravir 400 mg) film-coated tablets, for oral use; chewable tablets, for oral use; oral suspension and ISENTRESS® HD (raltegravir 600 mg) film-coated tablets, for oral use
- JANUMET® & JANUMET® XR
JANUMET® (sitagliptin and metformin HCI) 50/500 mg, 50/1000 mg tablets and JANUMET® XR (sitagliptin and metformin HCI extended-release) 50/500 mg, 50/1000 mg, 100/1000 mg tablets
Before prescribing JANUMET, please read the Prescribing Information, including the Boxed Warning about lactic acidosis.
Before prescribing JANUMET XR, please read the Prescribing Information, including the Boxed Warning about lactic acidosis.
- JANUVIA®
(sitagliptin) 25 mg, 50 mg, 100 mg tablets
- LAGEVRIO™
(molnupiravir) 200 mg capsules
- PIFELTRO®
PIFELTRO® (doravirine 100 mg) tablets
Before prescribing PIFELTRO, please read the accompanying Prescribing Information. The Patient Information also is available.
- PREVYMIS®
(letermovir) 240 mg, 480 mg tablets; Injection 20 mg/mL
- SEGLUROMET®
(ertugliflozin and metformin HCI) 2.5 mg/500 mg, 2.5 mg/1000 mg, 7.5 mg/500 mg, 7.5 mg/1000 mg tablets
Before prescribing SEGLUROMET, please read the Prescribing Information, including the Boxed Warning about lactic acidosis.
- SIVEXTRO®
(tedizolid phosphate) 200 mg injection, for intravenous use; 200 mg tablet, for oral use
- STEGLATRO®
(ertugliflozin) 5 mg, 15 mg tablets
- STEGLUJAN®
(ertugliflozin and sitagliptin) 5 mg/100 mg, 15 mg/100 mg tablets
- VERQUVO®
(vericiguat) tablets 2.5 mg, 5 mg, 10 mg
Before prescribing VERQUVO, please read the Prescribing Information, including the Boxed Warning about embryo-fetal toxicity.
- WELIREG™
(belzutifan) 40 mg tablets
Before prescribing WELIREG, please read the Prescribing Information, including the Boxed Warning about embryo-fetal toxicity.
Alliance Products*
- LENVIMA®**
(lenvatinib) capsules, 10 mg & 4 mg
- LYNPARZA®***
(olaparib) tablets, 150 mg
*These products are co-developed and co-commercialized with another manufacturer.
**LENVIMA® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
***LYNPARZA® is a registered trademark of the AstraZeneca group of companies.
Vermont
Pursuant to Vermont’s Pharmaceutical Marketer Price Disclosure Law, 18 V.S.A. § 4633, Merck is required to provide to Vermont prescribers pricing information about certain Merck products, as well as other products in the same therapeutic class. The “other products” listed are not necessarily interchangeable with the Merck product, nor should they be implied to have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.
Further, as required by Vermont law, the prices listed are derived from Average Wholesale Price, which is provided by a third party publisher. The prices paid by consumers may vary from the prices listed.
- BELSOMRA®
(suvorexant) 5, 10, 15, 20 mg tablets, for oral use, C-IV
- DELSTRIGO®
(doravirine 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg) tablets
Before prescribing DELSTRIGO, please read the accompanying Prescribing Information, including the Boxed Warning about posttreatment acute exacerbation of Hepatitis B.
- DIFICID®
(fidaxomicin) tablets 200 mg | oral suspension 200 mg/5 ml
- ISENTRESS® & ISENTRESS® HD
ISENTRESS® (raltegravir 400 mg) film-coated tablets, for oral use; chewable tablets, for oral use; oral suspension and ISENTRESS® HD (raltegravir 600 mg) film-coated tablets, for oral use
- JANUMET® & JANUMET® XR
JANUMET® (sitagliptin and metformin HCI) 50/500 mg, 50/1000 mg tablets and JANUMET® XR (sitagliptin and metformin HCI extended-release) 50/500 mg, 50/1000 mg, 100/1000 mg tablets
Before prescribing JANUMET, please read the Prescribing Information, including the Boxed Warning about lactic acidosis.
Before prescribing JANUMET XR, please read the Prescribing Information, including the Boxed Warning about lactic acidosis.
- JANUVIA®
(sitagliptin) 25 mg, 50 mg, 100 mg tablets
- LAGEVRIO™
(molnupiravir) 200 mg capsules
- PIFELTRO®
PIFELTRO® (doravirine 100 mg) tablets
Before prescribing PIFELTRO, please read the accompanying Prescribing Information. The Patient Information also is available.
- PREVYMIS®
(letermovir) 240 mg, 480 mg tablets; Injection 20 mg/mL
- SEGLUROMET®
(ertugliflozin and metformin HCI) 2.5 mg/500 mg, 2.5 mg/1000 mg, 7.5 mg/500 mg, 7.5 mg/1000 mg tablets
Before prescribing SEGLUROMET, please read the Prescribing Information, including the Boxed Warning about lactic acidosis.
- SIVEXTRO®
(tedizolid phosphate) 200 mg injection, for intravenous use; 200 mg tablet, for oral use
- STEGLATRO®
(ertugliflozin) 5 mg, 15 mg tablets
- STEGLUJAN®
(ertugliflozin and sitagliptin) 5 mg/100 mg, 15 mg/100 mg tablets
- VERQUVO®
(vericiguat) tablets 2.5 mg, 5 mg, 10 mg
Before prescribing VERQUVO, please read the Prescribing Information, including the Boxed Warning about embryo-fetal toxicity.
- WELIREG™
(belzutifan) 40 mg tablets
Before prescribing WELIREG, please read the Prescribing Information, including the Boxed Warning about embryo-fetal toxicity.
Alliance Products*